Skip to main content
Livermore
Livermore
ZHEN

NextCure, Inc.

NXTC
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001661059

In the last 90 days, NextCure, Inc. insiders filed 2 open-market purchases and 1 sale; 30 institutions reported holding it in 13F filings for Q2 2026, worth $2.78M in total; no superinvestor holds it.

Holders of 5% or more of NXTC

Holders whose latest Schedule 13D or 13G filing reports 5% or more of NextCure, Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of NXTC
HolderLatest formStakeChangeFirst filedLatest filingFiling
Simcere Zaiming, Inc.13G12.70%338.6K sharesNewAug 19, 20251 filingAug 19, 2025SEC
Affinity Asset Advisors, LLC13G/A7.17%191.9K shares–Nov 14, 20251 filingNov 14, 2025SEC
Squadron Capital Management LLC13G6.50%173.9K sharesNewOct 24, 20251 filingOct 24, 2025SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

5 Schedule 13D and 13G filings on NextCure, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on NXTC
Filed (ET)FilerFormStakeChangeEvent dateFiling
Nov 14, 20254:10 PM ETAffinity Asset Advisors, LLCand 1 other13G/A7.17%191.9K shares–Sep 30, 2025SEC
Oct 24, 20254:37 PM ETSquadron Capital Management LLCand 3 others13G6.50%173.9K sharesNewOct 21, 2025SEC
Aug 19, 20259:46 PM ETSimcere Zaiming, Inc.and 5 others13G12.70%338.6K sharesNewJun 20, 2025SEC
May 12, 202512:54 PM ETCitigroup Incand 3 others13G4.30%1.21M sharesNewBelow 5%Mar 31, 2025SEC
Feb 14, 20251:40 PM ETLogos Global Management LPand 4 others13G/A0.00%0 shares–Below 5%Dec 31, 2024SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell NextCure, Inc. shares.

No Form 144 notices for NextCure, Inc. are on file.